trial · primary record
4SCAR19 and 4SCAR22
B-cell Malignancies
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2026-07-31 |
| Primary endpoint | Safety of fourth generation anti CD19 and CD20/CD22/CD30/CD38/CD70/CD123 CAR-T cells in patients with relapsed B cell malignancies using CTCAE 4 standard to evaluate the level of adverse events standard to evaluate the level of adverse events |
| Registry ID | NCT03125577 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:40.150Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03125577
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.